5.11
-0.26 (-4.84%)
| Previous Close | 5.37 |
| Open | 5.35 |
| Volume | 11,353,113 |
| Avg. Volume (3M) | 5,608,585 |
| Market Cap | 906,889,152 |
| Price / Sales | 0.390 |
| Price / Book | 0.720 |
| 52 Weeks Range |
| Profit Margin | -39.66% |
| Operating Margin (TTM) | -8.73% |
| Diluted EPS (TTM) | -5.91 |
| Quarterly Revenue Growth (YOY) | -2.60% |
| Total Debt/Equity (MRQ) | 111.19% |
| Current Ratio (MRQ) | 1.68 |
| Operating Cash Flow (TTM) | 300.68 M |
| Levered Free Cash Flow (TTM) | 243.04 M |
| Return on Assets (TTM) | -3.01% |
| Return on Equity (TTM) | -54.49% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Bearish |
| Health Information Services (Global) | Bearish | Bearish | |
| Stock | Teladoc Health, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | -1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.40 |
|
Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Value |
| % Held by Insiders | 0.98% |
| % Held by Institutions | 74.10% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 11.00 (Deutsche Bank, 115.26%) | Buy |
| Median | 6.00 (17.42%) | |
| Low | 5.00 (BMO Capital, -2.15%) | Hold |
| 5.00 (Evercore ISI Group, -2.15%) | Hold | |
| Average | 6.96 (36.20%) | |
| Total | 4 Buy, 7 Hold | |
| Avg. Price @ Call | 5.32 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Deutsche Bank | 10 Mar 2026 | 11.00 (115.26%) | Buy | 5.57 |
| Citigroup | 03 Mar 2026 | 6.00 (17.42%) | Hold | 5.10 |
| 09 Jan 2026 | 9.00 (76.13%) | Hold | 7.46 | |
| Oppenheimer | 03 Mar 2026 | 7.00 (36.99%) | Buy | 5.10 |
| BMO Capital | 26 Feb 2026 | 5.00 (-2.15%) | Hold | 5.35 |
| Canaccord Genuity | 26 Feb 2026 | 10.00 (95.69%) | Buy | 5.35 |
| Evercore ISI Group | 26 Feb 2026 | 5.00 (-2.15%) | Hold | 5.35 |
| Leerink Partners | 26 Feb 2026 | 5.50 (7.63%) | Hold | 5.35 |
| Piper Sandler | 26 Feb 2026 | 9.00 (76.13%) | Buy | 5.35 |
| Stifel | 26 Feb 2026 | 6.00 (17.42%) | Hold | 5.35 |
| TD Cowen | 26 Feb 2026 | 6.00 (17.42%) | Hold | 5.35 |
| Wells Fargo | 26 Feb 2026 | 6.00 (17.42%) | Hold | 5.35 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DIVITA CHARLES III | - | 5.47 | -27,731 | -151,689 |
| Aggregate Net Quantity | -27,731 | |||
| Aggregate Net Value ($) | -151,689 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 5.47 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| DIVITA CHARLES III | Officer | 11 Mar 2026 | Sell (-) | 27,731 | 5.47 | 151,689 |
| DIVITA CHARLES III | Officer | 10 Mar 2026 | Option execute | 64,653 | - | - |
| Date | Type | Details |
|---|---|---|
| 05 Mar 2026 | CNBC | Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S. |
| 05 Feb 2026 | Announcement | Teladoc Health to Announce Fourth Quarter 2025 Financial Results |
| 12 Jan 2026 | Announcement | Teladoc Health Launches Enhanced 24/7 Care Service |
| 05 Jan 2026 | Announcement | Teladoc Health to Participate in Upcoming Investor Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |